In March, the FDA cleared Dexcom’s Stelo, making it the first glucose biosensor that doesn’t require a prescription. The small, wearable device, worn on the back of the upper arm, is designed ...

The introduction of sensors like G6 and G7 in international markets also fueled revenue growth. Dexcom anticipates strong growth from its recent product launches and international expansions ...

Among its flagship products are the Dexcom G6 and G7 integrated CGM systems, which play an important role in helping individuals monitor their glucose levels effectively. As a prominent player in ...

Its products include DexCom G4 PLATINUM System, DexCom G5 Mobil, DexCom G6, and DexCom Share. Read More on DXCM: DexCom NewsMORE Related Stocks Indices ...

Its products include DexCom G4 PLATINUM System, DexCom G5 Mobil, DexCom G6, and DexCom Share. Read More on DXCM: DexCom NewsMORE Related Stocks Indices Commodities ...

DexCom is a pioneer in the development of continuous glucose monitoring (CGM) systems, which are used by people managing diabetes. Its innovative devices like the G6 and G7 have set the standard ...

DXCM's third-quarter 2024 earnings and revenues surpass expectations, fueled by global growth in CGM adoption, strong Sensor sales and expansion into new markets. DexCom stock was falling Friday ...

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 0.3% on Friday. Shares of Capri Holdings Limited CPRI fell sharply in today's pre-market trading following ...

Well, I'll start. Every study in these AID systems has been done with the DexCom sensor. So there aren't any head-to-head studies. They've all been run with DexCom, at least with our pump partners ...

Reporting its third-quarter results after market hours Thursday, DexCom said its revenue amounted to $994 million for the period. This was, however, only 2% higher on a year-over-year basis for ...